BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders
BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - April 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging that the Company violated federal securities laws.
纽约，纽约-(Newsfile Corp.-2021年4月9日)-克莱恩律师事务所(Klein Law)宣布，已代表股东提起集体诉讼蓝鸟生物股份有限公司(Bluebird Bio，Inc.)(纳斯达克市场代码：BLUL)指控该公司违反了联邦证券法。
Class Period:May 11, 2020andNovember 4, 2020
上课时间：2020年5月11日和2020年11月4日
Lead Plaintiff Deadline:April 13, 2021
首席原告截止日期：2021年4月13日
Learn more about your recoverable losses in BLUE:
以蓝色了解有关您的可挽回损失的更多信息：
http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=14551&from=5
Http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=14551&from=5
The filed complaint alleges that bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
起诉书称，蓝鸟生物公司做出了重大虚假和/或误导性陈述和/或未能披露：(1)支持蓝鸟公司提交用于SCD的LentiGlobin的BLA的数据不足以证明药品的可比性；(2)被告淡化了与新冠肺炎大流行有关的干扰对该公司提交用于SCD的LentiGlobin的BLA时间表的可预见影响，特别是在制造方面；(3)由于上述所有情况，这是可以预见的。及(Iv)因此，本公司的公开陈述在所有相关时间均属重大虚假及误导性陈述。
Shareholders have until April 13, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
股东可以在2021年4月13日之前向法院请愿，要求获得主要原告地位。你分享任何赔偿的能力并不需要你担任主要原告。
For additional information about the BLUE lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
有关蓝色诉讼的更多信息，请联系Esq的J.Klein。请拨打212-616-4899或点击上面的链接。
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
J·克莱因(J.Klein)，Esq.在全国范围内代表投资者并参与涉及金融欺诈的证券诉讼。律师广告。先前的结果不能保证类似的结果。
CONTACT:
联系方式：
J. Klein, Esq.
J·克莱因(J.Klein)，Esq.
Empire State Building
帝国大厦
350 Fifth Avenue
第五大道350号
59th Floor
59楼
New York, NY 10118
纽约，纽约，10118
jk@kleinstocklaw.com
邮箱：jk@kleinstocklaw.com
Telephone: (212) 616-4899
电话：(212)616-4899
Fax: (347) 558-9665
传真：(347)558-9665
www.kleinstocklaw.com
Www.kleinstocklaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80026
要查看本新闻稿的源版本，请访问https://www.newsfilecorp.com/release/80026
译文内容由第三方软件翻译。